Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF – Research Report) and Immunocore Holdings (IMCR – Research Report).
Roche Holding AG (RHHVF)
In a report released today, Luisa Hector from Berenberg Bank maintained a Hold rating on Roche Holding AG, with a price target of CHF265.00. The company’s shares closed last Wednesday at $245.61, close to its 52-week low of $237.81.
According to TipRanks.com, Hector is a 4-star analyst with an average return of
Currently, the analyst consensus on Roche Holding AG is a Hold with an average price target of $275.72, an 11.8% upside from current levels. In a report issued on April 8, Barclays also maintained a Hold rating on the stock with a CHF250.00 price target.
See the top stocks recommended by analysts >>
Immunocore Holdings (IMCR)
In a report released today, Gil Blum from Needham maintained a Buy rating on Immunocore Holdings, with a price target of $81.00. The company’s shares closed last Wednesday at $58.81.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
Currently, the analyst consensus on Immunocore Holdings is a Strong Buy with an average price target of $84.27, representing a 47.2% upside. In a report issued on April 1, Barclays also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RHHVF:
- Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer’s disease diagnosis
- Roche announces CE Mark for Ventana HER2 Rabbit Monoclonal Primary RxDx
- Roche upgraded to Buy from Hold at Kepler Cheuvreux
- Roche receives FDA approval for molecular test to screen blood donors for malaria
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
